Supernus Pharmaceuticals Says Postpartum Depression Treatment Receives Authorization From Health Canada
I'm PortAI, I can summarize articles.
08:43 AM EST, 12/09/2025 (MT Newswires) -- Supernus Pharmaceuticals ( SUPN ) said Tuesday that Health Canada issued a notice of compliance for Zurzuvae (zuranolone) for the treatment of moderate or severe postpartum depression in adults following childbirth.Zurzuvae is a once-daily, 14-day oral single-course neuroactive steroid treatment for women with postpartum depression, Supernus Pharmaceuticals ( SUPN ) said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments